Progyny, Inc. (NASDAQ:PGNY) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. reduced its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 75.3% in the 4th quarter, HoldingsChannel reports. The fund owned 50,548 shares of the company’s stock after selling 154,125 shares during the quarter. Russell Investments Group Ltd.’s holdings in Progyny were worth $872,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. GAMMA Investing LLC boosted its holdings in Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after purchasing an additional 1,246 shares in the last quarter. Signaturefd LLC boosted its holdings in shares of Progyny by 1,355.0% in the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock valued at $25,000 after buying an additional 1,355 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after buying an additional 1,526 shares during the last quarter. KBC Group NV grew its position in shares of Progyny by 84.6% in the 4th quarter. KBC Group NV now owns 4,669 shares of the company’s stock valued at $81,000 after buying an additional 2,140 shares during the last quarter. Finally, Entropy Technologies LP raised its stake in Progyny by 5.5% during the 4th quarter. Entropy Technologies LP now owns 47,883 shares of the company’s stock worth $826,000 after acquiring an additional 2,499 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Analysts Set New Price Targets

PGNY has been the topic of several research reports. Canaccord Genuity Group raised their price objective on Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, February 28th. BTIG Research upgraded Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price target on the stock in a research note on Monday, March 31st. Bank of America boosted their price objective on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Finally, JPMorgan Chase & Co. raised their target price on shares of Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $23.64.

Progyny Stock Performance

Shares of Progyny stock opened at $21.37 on Tuesday. The company has a market cap of $1.83 billion, a P/E ratio of 36.85, a PEG ratio of 2.39 and a beta of 1.33. The firm has a fifty day moving average of $21.93 and a two-hundred day moving average of $18.92. Progyny, Inc. has a one year low of $13.39 and a one year high of $33.84.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.